Together, our findings indicate that CDK6 and LRP1B have significant potential as indicators of prognosis and lymph node metastasis in patients with EJA and could be targeted for molecular targeted therapy. The gene discussed is LRP1B; the disease is metastatic malignant neoplasm in the lymph nodes.